Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QPOP-guided doublet therapy for relapsed/refractory peripheral T-cell lymphoma
ACTRN12626000088347Phase 2Recruiting
- Sponsor
- National University Hospital
- Start
- Nov 2025
- Modality
- Small Molecules, Peptides, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romidepsin, vinorelbine, gemcitabine, bortezomib, etoposide and 14 more in peripheral T-cell lymphoma (PTCL), sponsored by National University Hospital. Primary endpoint: Overall response rate. Started Nov 2025; status: recruiting.
02
Drugs
romidepsinvinorelbinegemcitabinebortezomibetoposide
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ACTRN12626000088347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000088347.